USO08003783B2 (12) United States Patent (10) Patent No.: US 8,003,783 B2 Vicker et al. (45) Date of Patent: Aug. 23, 2011 (54) 17B-HYDROXYSTEROID DEHYDROGENASE OTHER PUBLICATIONS INHIBITORS Martin R. Tremblay, et al "Overview of a Rational Approach to (75) Inventors: Nigel Vicker, Slough (GB); Harshani DesignType I 17 B-Hydroxysteroid Dehydrogenase Inhibitors With Rithma Ruchiranani Lawrence, Slough out Estrogenic Activity: Chemical Synthesis and Biological Evalua (GB); Gillian Margaret Allan, Slough tion” 66(4) J. Steroid Biochem (1998): 179-191. (GB); Christian Bubert, Slough (GB); (Continued) Delphine Sophie Marion Fischer, Slough (GB); Atul Purohit, Slough Primary Examiner — Barbara P. Badio (GB); Michael John Reed, Slough Assistant Examiner — Sara E Townsley (GB); Barry Victor Lloyd Potter, (74) Attorney, Agent, or Firm — Frommer Lawrence & Slough (GB) Haug LLP; Sandra Kuzmich; Russell A. Garman (73) Assignee: Sterix Limited, Slough, Berkshire (GB) (57) ABSTRACT (*) Notice: Subject to any disclaimer, the term of this There is provided a compound of Formula (III) patent is extended or adjusted under 35 U.S.C. 154(b) by 1622 days. 3 Formula (III) (21) Appl. No.: 11/234,868 R (22) Filed: Sep. 23, 2005 RI (65) Prior Publication Data US 2006/OO74060 A1 Apr. 6, 2006 N Related U.S. Application Data 3 yCa (63) Continuation-in-part of application No. R2 PCT/GB2004/001234, filed on Mar. 22, 2004. R4 (51) Int. Cl. wherein A6 IK3I/58 (2006.01) R" is a selected from an alkyloxyalkyl group, a nitrile group, CO7I 71/00 (2006.01) alkylaryl group, alkenylaryl group, alkylheteroaryl group, (52) U.S. Cl. .......................................... 540/49; 514/176 alkenylheteroaryl group, =N-O-alkyl or =N-O H (58) Field of Classification Search .................... 540/49; group, branched alkenylalkyl-alcohol group, amide or 514f176 alkylamide or —CHO so that R together with R provide See application file for complete search history. the enol tautomer or R together with R form a pyrazole, wherein(a)R’ is =N O-alkylor=N-O-H group, (b) (56) References Cited the pyrazole is substituted with one of alkyl-OH group, alkyl ester group, alkyloxyalkyl group, branched alkyl U.S. PATENT DOCUMENTS group, and an amide and/or (c) the 2-position is Substituted with a group selected from —OH and —O-hydrocarbyl or 3,047,568 A T. 1962 Kissman et al. a heteroaryl ring; (Continued) R’ is selected from —OH and a sulphamate group; and R is selected from —OH or =O; wherein the ring system FOREIGN PATENT DOCUMENTS may be further substituted with one or more hydroxyl, DE 1176 131 T 1961 alkyl, alkoxy, alkinyl or halo Substituents. (Continued) 19 Claims, 1 Drawing Sheet SS HOSO ES El E. E. Tyge at al 2. 8 2. res, set r US 8,003,783 B2 Page 2 U.S. PATENT DOCUMENTS Gorski J., et al., Hormones receptors: Studies on the interaction of 3,163,641 A 12, 1964 Christiansen et al. estrogens with uterus, Recent Prog. Horm. Res., 1968, vol. 24, p. 3,398,140 A 8, 1968 Clinton 45-80. 5,585,405 A * 12/1996 Labrie et al. .................. 514,733 Gupta, et al., Synthesis and biological activity of Some D-ring modi 5,880,115 A 3/1999 Li et al. fied oestrone derivative, Ind. J. Chem. 1999, vol. 38B, p. 563-571. 6,046,186 A 4/2000 Tanabe et al. Heer, et al., Uber Steroide, Marrianol-und Doisynoisaure, Uber FOREIGN PATENT DOCUMENTS oestrogene carbonsauren II. Heiv. Chim. Acta. 1945, vol. 28, p. 156-165. GB 1033520 6, 1966 GB 1096732 12/1967 Horiuchi, et al., Regioselective 2-Iodination of Estradiol, Estriol & GB 233.1987 6, 1999 Oestrone, J. Chem. Soc. Chem. Commun., 1982, p. 671-672. WO WO O2, 16392 2, 2002 Holli K., et al. Lumpectomy with or without postoperative radio WO O2,32409 4/2002 therapy for breast cancer with favourable prognostic features: results WO WO O2/O58634 8, 2002 ofa randomized study, Br. J. Cancer, 2001, vol. 84. No. 2, p. 164-169. Horwitz K. B., et al., Nuclear mechanism of estrogen action: effects OTHER PUBLICATIONS of oestradiol and anti-estrogens on estrogens receptors and nuclear Maninder Minu, et al. “Synthesis and Biological Activity of receptor processing, J. Biol. Chem., 1978, vol. 253, p. 8185-8192. 16-arylidene derivatives of Estrone and Estrone Methyl Ether'42 (1) Horwitz, K.B. et al. Oestrogen control of progesterone receptor in human breast cancer; role of oestradiol and antiestrogen, Endocri Indian Journal of Chemistry Section B (2003): 166-172. nology, 1978, vol. 103, p. 1742-1751. Donald Poirier, et al. "A Multidetachable Sulfamate Linker Success Jin J.-Z. et al., Human estrogenic 17 -hydroxysteroid fully Used in a Solid-Phase Strategy to Generate Libraries of dehydrogenase : predominance of oestrone reduction and its induc Sulfamate and Phenol Derivatives' 12 Bioorganic & Medicinal tion by NADPH, Biochem, Biophys. Res., 1999, 259, p. 489-493. Chemistry Letters (2002) 2833-2838. Jordan V.C.. The Strategic use of antiestrogens to control the devel Tremblay et al., “Synthesis of 16-(Bromoalkyl)-Estradiols having opment and growth of breast cancer, Cancer, 1992, vol. 70, p. 977 Inhibitory Effect on Human Placental Estradiol 17B-Hydroxysteroid 982. Dehydrogenase (173-HSD Type 1)”. Bioorganic and Medicinal Kaae S., et al., Does simple mastectomy followed by irradiation offer Chemistry, vol. 3, No. 5, pp. 505-523 (1995). the Survival comparable to radical procedures. International Journal Liviu Constantin Ciobanu et al., “Nonsteroidal compounds designed of Radiation Oncology, Biology, Physics, 1977, vol. 2, p. 1163-1166. to mimic potent steroid sulfatase inhibitors”, Journal of Steroid Bio Labrie F. At the cutting edge, Intracrinology, Mol. Cell. Endocrinolo., chemistry & Molecular Biology, vol. 80, pp. 339-353, (2002). 1991, 78, C113-118. Adamski, et al., Molecular cloning of a novel widely expressed Lebail et al., Aromatase and 173-hydroxysteroid dehydrogenase human 80 kDa 17B-hydroxysteroid dehydrogenase IV, Biochem. J., inhibition by flavinoids, Cancer Lett., 1998, vol. 133, p. 101-106. 1995, vol. 311, p. 437-443. Li P.-K. et al., Development of potent non-estrogenic oestrone Agnusdei D., et la. B. Ann. Endocrinol, 1999, vol. 60, No. 3, p. Sulphatase inhibitors, Steroids, 1998, 63, p. 425-432. 242-246. Lin et al., 3D structure of human estrogenic 17 B-HSD: binding with Appeletal. Uberdashydrazidosulpfamid, Chem. Ber, 1958, vol.91. various steroids, J. Steroid. Biochem. Mol. Biol., 1999, vol. 69, p. p. 1339-1341. 425-429. Breton, et al., The structure of a complex of human 17 Loev et al., Alkylphenols related to the poison ivy principle, An B-hydroxysteroid dehydrogenase with oestradiol and NADP8 iden improved method of synthesis involving the Na-Butanol cleavage of tifies two principal targets for the design of inhibitors, Structure benzyl ethers, J. Am. Chem. Soc., 1956, vol. 78 p. 6095-6101. (Lond.), 1996, vol. 4, p. 905-915. Makela, et al., Inhibition of 17 beta-hydroxysteroid oxidoreductase Castiglione-Gertsch J. New aromatase inhibitors: more selectivity, by flavonids in breast and prostate cancer cells, Proc. Soc. Exp. Biol. less toxicity, unfortunately, the same activity, Eur, J. Cancer, 1996, Med. 1998, vol. 217, p. 310-316. vol. 32A, p. 393-395. Malini B., et al., Inhibition of steroid Sulphatase activity by tricyclic Claussner A. et al., J. Steroid. Biochem, 1992, vol. 41, p. 609-614. coumarin sulfamates, J. Steroid Biochem. Molecular Biol., 2000, vol. Coldham et al. A possible mechanism for increased breast cell pro 75, p. 253–258. liferation by progestins through increased reductive 17 Matkovics, et al., Rearrangement of steroids, VII, Schmidt reaction B-hydroxysteroid dehydrogenase activity, Int. J. Cancer, 1990, vol. and Beckmann rearrangement of oestrone and its derivatives, Acta 45, p. 174-178. Chim. Acad. Scien. Hung. 1974, vol. 80, p. 79-87. Collins et al., The estrogenic and anti-Oestrogenic activities of Miller B.A., et al. (eds), Racial/Ethnic patterns of Cancer in the phytochemicals with the human estrogen receptor expressed in yeast, United States, 1988-1992, National Cancer Institute, 1996. Steroids, 1997, vol. 62, p. 365-372. Miller W.R., Aromatase Inhibitors—where are we now?, Br. J. Can Coulson C.J., Steroid biosynthesis and action, 2" edition, Molecular cer, 1996, vol. 73, p. 415-417. Mechanism of Drug Action, 1994, p. 95-122. Nicholls P.J., Breast Cancer Management: Science and Care Deyashiki, et al., Molecular cloning and characterization of mouse Together, Pharm.J. 1997, vol. 259, p. 459-470. oestradiol 17 f-dehydrogenase (A-specific), a member of the Numazawa, et al., J. Chem. Soc. Chem. Commun., 1983, vol. 9 p. aldoketoreductase family, J. Biol. chem., 1995, vol. 270, p. 10461 533. 10467. Okada et al. Efficient general method for sulfamoylation of a Duncan, et al. Inhibition of oestrone Sulphatase activity by estrone hydroxyl group, Tet. Lett., 2000, vol. 41, p. 7047-7051. 3-methyl-thiophosphonate: a potential therapeutic agent in breast Peltoketo H., et al., Complete amino acid sequence of human placen cancer, Cancer Res., 1993, vol. 53, p. 298-303. tal 17B-hydroxysteroid dehydrogenase deduced from cDNA, FEBS Early Breast Cancer Trialists' Collaborative Group. Effects of adju Lett., 1988, vol. 239, No. 1, p. 73-77. vant Tamoxifen and of cytotoxic therapy on mortality in early breast Peltoketo H., et al., 17B-hydroxysteroid dehydrogenase (HSD)/ 17 cancer, N. Eng. J. Med., 1988, vol. 319, p. 1681-1692. ketosteroid reductase (KSR) family, nomenclature and main charac Geissler et al., Male pseudohermaphroditism caused by mutation of teristics of the 17 HSD/KSR enzymes, J. Mol. Endocrinol. 1999, vol. testicular 17 B-hydroxysteroid dehydrogenase 3, Nat. Genet., 1994, 23, No. 1, p. 1-11. vol. 7, p. 34-39. Penning T.M., Molecular endocrinology of hydroxysteroid Ghosh, et al., Structure of the human estrogenic 17 beta dehydrogenases, Endocrine Reviews, 1997, vol.